Venous thromboembolism with EGFR monoclonal antibody necitumumab in stage IV non-small cell lung cancer: A retrospective cohort analysis

Metastatic non-small cell lung cancer (NSCLC) is a recognized risk factor for VTE. Some systemic treatments may increase this risk further. Here, we present the risk of VTE and its prognostic significance for patients treated with chemotherapy (chemo) and the EGFR monoclonal antibody necitumumab (neci) for metastatic NSCLC.

Source: Thrombosis Research - May 7, 2018 Category: Hematology Authors: Kelvin Young, Luis Paz-Ares, Nick Thatcher, David R. Spigel, Javad Shahidi, Victoria Soldatenkova, Gerrit Grau, Raffael Kurek, Frances A. Shepherd Tags: Full Length Article Source Type: research